MCL1 and neoplasm: It has been established that MCL-1 protein degradation is compromised observed subsequent to FBXW7 mutation or deletion within tumor cells, leading to resistance to anti-microtubule drugs such as paclitaxel and vincristine (Wertz et al., 2011).